Clinical trials: Pulmonary Artery Hypertension
Pulmonary Arterial Hypertension
Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States
The Opsumit Users registry (OPUS; NCT02126943) was developed to characterize the safety profile of Opsumit and to describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-marketing…
- Trial name
- OrPHeUS (NCT03197688)
- Testing
- Notapplicable
- Where
- 106 sites in United States, Puerto Rico
- Volunteers
- 2,200 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension (PAH), Sleep-disordered Breathing (SDB)
PAH-SDB: Sleep-Disordered Breathing and Outcomes in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease characterized by increased pulmonary vascular resistance, right ventricular dysfunction, and clinically important morbidity and mortality.
- Trial name
- PAH-SDB (NCT07852403)
- Testing
- Standardized Overnight Sleep and Cardiorespiratory Monitoring
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Chinese Pulmonary Vascular Disease Research Group
Interstitial Lung Disease, Comorbidities and Coexisting Conditions
Taiwan Interstitial Lung Disease Multi-center Investigation and Registry
The Taiwan Interstitial Lung Disease (ILD) Multi-center Investigation and Registry aims to evaluate the long-term outcomes of patients with fibrotic interstitial lung disease.
- Conditions
- Interstitial Lung Disease, Comorbidities and Coexisting Conditions, Pulmonary Arterial Hypertension, Treatment Adherence
- Trial name
- TAILI (NCT06476470)
- Where
- Taiwan
- Volunteers
- 10,000 people
- Sponsor
- Taichung Veterans General Hospital
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension
Pulmonary hypertension represents a challenging and heterogeneous condition that is associated with high mortality and morbidity if left untreated.
- Trial name
- AIPHY (NCT05566002)
- Testing
- Right heart catheterization
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Chinese Pulmonary Vascular Disease Research Group
Pulmonary Arterial Hypertension (PAH)
Telerehabilitation in Pulmonary Arterial Hypertension
Context: Pulmonary arterial hypertension (PAH) causes severe exercise intolerance and reduced quality of life, while access to supervised rehabilitation remains limited.
- Trial name
- TRHP-001 (NCT07799675)
- Testing
- Home-based telerehabilitation program
- Where
- Spain
- Volunteers
- 34 people
- Sponsor
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Pulmonary Artery Hypertension
Evaluation of Respiratory Muscle in Patient With Pulmonary Arterial Hypertension
The aim of the study is that evaluation of basic and accessory respiratory muscles and their relationship of six minute walk test in patient with pulmonary arterial hypertension (PAH)
- Trial name
- NCT05056532
- Testing
- patient assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Giresun University
Pulmonary Arterial Hypertension
Modulating Effects of Lisinopril on Sildenafil Activity in Pulmonary Arterial Hypertension(PAH)( MELISSA)
Patients with pulmonary arterial hypertension(PAH) suffer from chronic shortness of breath, and have impaired survival related to progressive right ventricular failure.
- Trial name
- MELISSA (NCT01181284)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mayo Clinic
Pulmonary Hypertension
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521 given orally for 12 weeks, in patients with symptomatic Pulmonary Arterial Hypertension (PAH).
- Trial name
- PATENT-1 (NCT00810693)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 122 sites in United States, Argentina and 28 more
- Volunteers
- 445 people
- Sponsor
- Bayer
Primary and Secondary Pulmonary Hypertension
Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary Hypertension
The aim of this trial is to evaluate the efficacy of type-5 phosphodiesterase inhibitors (sildenafil) in primary and secondary pulmonary hypertension
- Trial name
- NCT00155714
- Testing
- type-5 phosphodiesterase Inhibitor (Sildenafil)
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety
As sitaxsentan is the agent most highly selective for ETA (Endothelin Type A (receptor)), and does not significantly impact sildenafil pharmacokinetics the combination of most promise for pulmonary arterial hypertension (PAH)…
- Trial name
- NCT00796510
- Testing
- Sitaxsentan, Sitaxsentan and Sildenafil
- Where
- 3 sites in United States, Romania and 1 more
- Volunteers
- 3 people
- Sponsor
- Pfizer
Pulmonary Arterial Hypertension
Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)
The objectives of the RELIEVE-PAH study are to obtain first-in-human experience with the study device in patients with severe pulmonary arterial hypertension, including evidence of initial safety, device performance and possible…
- Trial name
- RELIEVE-PAH (NCT03838445)
- Testing
- V-Wave Interatrial Shunt
- Where
- 3 sites in United States, Mexico
- Volunteers
- 9 people
- Sponsor
- V-Wave Ltd
Pulmonary Arterial Hypertension, Chronic Obstructive Pulmonary Disease
Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching
The purpose of this study is to see how inhaled treprostinil sodium (Tyvaso) affects the amount of air and blood that reach the alveoli, or tiy air sacs, in the lungs of patients with Group 1 Pulmonary Arterial Hypertension with…
- Trial name
- NCT01494896
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- University of Florida
Pulmonary Arterial Hypertension
miRNA and Myokines in Patients With PAH
The overall objective of this study is to fulfill the Pilot study (miRNA and Myokines Acutely-expressed During Exercise) goal to Investigate the excretion of skeletal muscle-derived miRNA and myokines in patients with pulmonary…
- Trial name
- NCT03905083
- Testing
- Exercise Rehab
- Where
- United States
- Sponsor
- University of Pittsburgh
Pulmonary Hypertension
Upfront Combination Pulmonary Arterial Hypertension Therapy
To evaluate the safety and efficacy of first-line combination therapy using riociguat with ambrisentan in patients with Pulmonary Arterial Hypertension (PAH).
- Trial name
- NCT03809156
- Testing
- Riociguat Oral Product
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- University of Calgary
Pulmonary Arterial Hypertension
Correlation of LONGterm Wrist ACTigraphy Recorded Physical Performance & 6-minute Walk Distance in Patients With Pulmonary Arterial Hypertension
The objective of the study is to monitor physical activity longitudinally with a wrist activity tracker specifically in PAH patients newly initiating ERA therapy and to assess the correlation with the 6MWD at different time…
- Trial name
- LONGACT (NCT02309463)
- Testing
- Endothelin receptor antagonist therapy
- Sponsor
- Actelion
Idiopathic Pulmonary Arterial Hypertension, Cardiomyopathy
Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing
The primary purpose of this study is to compare the number of participants with reversible pulmonary hypertension (vasoreactivity) due to nitric oxide for inhalation and oxygen as compared to 100% oxygen.
- Trial name
- NCT00626028
- Testing
- Nitric Oxide for inhalation, Oxygen, Nitric Oxide plus Oxygen
- Where
- 18 sites in United States, France and 3 more
- Volunteers
- 136 people
- Sponsor
- Mallinckrodt
Hypertension, Pulmonary
Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension
The primary objective of this study is to evaluate the effect of GSK1325760A on improvement in exercise capacity in subjects with pulmonary arterial hypertension (PAH).
- Trial name
- NCT00540436
- Testing
- GSK1325760A
- Where
- 15 sites in Japan
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Elevated Pulmonary Artery Pressure
Telerehabilitation in Patients With Elevated Pulmonary Artery Pressure
The goal of this clinical trial is to learn if synchronous telerehabilitation is effective in patients with elevated pulmonary artery pressure identified by echocardiography (systolic pulmonary artery pressure ≥50 mmHg).
- Trial name
- NCT07535398
- Testing
- Synchronous Telerehabilitation, Breathing and Posture Exercises
- Where
- Turkey (Türkiye)
- Volunteers
- 12 people
- Sponsor
- Marmara University
Pulmonary Arterial Hypertension
Beta-blockers in Pulmonary Arterial Hypertension
The investigators will conduct a, randomized, phase 2, placebo-controlled, double-blinded, crossover trial of carvedilol in 26 PAH patients with World Health Organization functional class II or III symptoms and RV ejection…
- Trial name
- NCT02507011
- Testing
- Carvedilol
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Minnesota
Pulmonary Hypertension
Mexican Registry of Pulmonary Hypertension
Prospective multicenter registry including incident patients and prevalent patients which pretends to identify clinical characteristics, treatment trends in-hospital and four years follow-up outcome through major adverse…
- Trial name
- REMEHIP (NCT02252705)
- Volunteers
- 875 people
- Sponsor
- Remehip